Log In
Print
BCIQ
Print
Print this Print this
 

Sym004

  Manage Alerts
Collapse Summary General Information
Company Symphogen A/S
DescriptionCombination of 2 anti-EGFR mAbs against 2 distinct and non-overlapping epitopes in the extracellular domain III of EGFR
Molecular Target Epidermal growth factor receptor (EGFR)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$622.6M

$25.2M

$597.4M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today